

## Peer-reviewed publications

Memon AA, Weber B, Winterdahl M, Jakobsen S, Meldgaard P, Madsen HHT, **Keiding S**, Nexø E, Sørensen BS. PET imaging of patients with non-small cell lung cancer employing an EGF-receptor targeting drug as tracer. *British J Cancer* 2011 *in press*.

Iversen S, **Keiding S**, Mouridsen K, Ott P, Vilstrup H. Transjugular intrahepatic portosystemic shunt does not alter cerebral blood flow. *Clin Gastroent Hepatol* 2011 *in press*.

Sørensen M, Mikkelsen KS, Frisch K, Bass L, Bibby BM, **Keiding S**. Hepatic galactose metabolism quantified in humans using 2-<sup>18</sup>F]fluoro-2-deoxy-D-galactose PET/CT. *J Nucl Med* 2011 52:1566–1572.

Bass L, Sørensen M, Munk OL, **Keiding S**. Analogue tracers and lumped constants in capillary beds. *J Theor Biol* 2011; 285:177–181.

Dam G, **Keiding S**, Munk OL, Ott P, Buhl M, Vilstrup H, Bak LK, Waagepetersen HS, Schousboe A, Møller N, Sørensen M. Branched-chain amino acids increase arterial blood ammonia in spite of enhanced intrinsic muscle ammonia metabolism in patients with cirrhosis and healthy subjects. *Am J Physiol Liver Gastroent* 2011; 301:G269–277.

Sørensen M, Frisch M, Bender D, **Keiding S**. The potential use of 2-<sup>18</sup>F]fluoro-2-deoxy-D-galactose as a PET/CT tracer for detection of hepatocellular carcinoma. *Eur J Nucl Med Molecular Imaging* 2011; 38:1723–1731.

Winterdahl M, Munk OL, Sørensen M, Mortensen FV, **Keiding S**. Hepatic blood perfusion measured by 3-min dynamic FDG PET in pigs. *J Nucl Med* 2011;52:1119–1124.

Weber B, Winterdahl M, Memon AA, Sørensen BS, **Keiding S**, Sørensen L, Nexø E, Meldgaard P. Erlotinib accumulation in brain metastases from non-small cell lung cancer. Visualisation by PET in a patient harbouring a mutation in the epidermal growth factor receptor. *J Thoracic Oncol* 2011;6:1287–1289.

Leke R, Bak LB, Iversen P, Sørensen M, **Keiding S**, Vilstrup H, Ott P, Portela LV, Schousboe A, Waagepetersen HS. Neuronal synthesis of GABA is coupled to energy-generating pathways in a rat model of chronic hepatic encephalopathy. *J Neurochem* 2011; 117:824–832.

Dadsetan S, Bak LB, Sørensen M, **Keiding S**, Vilstrup H, Ott P, Leke R, Schousboe, Waagepetersen HS. Inhibition of glutamine synthesis induces glutamate dehydrogenase-dependent ammonia fixation into alanine in co-cultures of astrocytes and neurons. *Neurochem Int* 2011; 59:482–488.

Frisch K, Bender D, **Keiding S**, Sørensen M. Nucleophilic radiosynthesis of 2-<sup>[18F]</sup>fluoro-2-deoxy-D-galactose from Talose triflate and biodistribution in a porcine mode. *Nuc Med Biol* 2011; 38: 477–483.

Winterdahl M, **Keiding S**, Sørensen M, Mortensen FV, Alstrup AKO, Munk OL. Tracer input for kinetic modelling of liver physiology determined without sampling portal venous blood in pigs. *Eur J Nucl Med Mol Imaging* 2011; 38: 263–270.

Lange A, Grønbæk H, Vilstrup H, **Keiding S**. Age-dependency of galactose elimination capacity in healthy children and children with chronic liver disease. *Scand J Gastroent* 2011; 46: 197–200.

Leke R, Bak LK, Anker M, Melø TM, Sørensen M, **Keiding S**, Vilstrup H, Ott P, Portela LV, Sonnewald U, Schousboe A, Waagepetersen H S. Detoxification of ammonia in mouse cortical GABAergic cell cultures increases neuronal oxidative metabolism and reveals an emerging role for release of glucose-derived alanine. *Neurotox Res* 2011; 19: 496–510.

Mortensen LS, Buus S, Nordmark M, Bentzen L, Munk OL, **Keiding S**, Overgaard J. Identifying hypoxia in human tumors: a correlation study between <sup>18</sup>F-FMISO PET and the Eppendorf oxygen-sensitive electrode. *Acta Oncol* 2010; 49: 934–940.

Gjedde A, **Keiding S**, Vilstrup H, Iversen P. No oxygen delivery limitation in hepatic encephalopathy. *Metab Brain Dis* 2010; 25: 57–63.

**Keiding S**, Sørensen M, Munk OL, Bender D. Human <sup>13</sup>N-ammonia PET studies: The importance of measuring <sup>13</sup>N-ammonia metabolites in blood. *Metab Brain Dis* 2010; 25: 49–56.

Gjedsted J, Gormsen L, Buhl M, Nørrelund H, Schmitz O, **Keiding S**, Tønnesen E, Møller N. Forearm and leg amino acid metabolism in the basal state and during combined insulin and amino acid stimulation after a 3 day fast. *Acta Physiol* 2009 2009; 197: 197–205.

Jepsen P, Vilstrup H, Ott P, **Keiding S**, Andersen PK, Tygstrup N. The galactose elimination capacity and mortality in 781 Danish patients with newly-diagnosed liver cirrhosis: a cohort study. *BMJ Gastroenterol* 2009; 9: 50–56.

Dam G, Sørensen M, Munk OL, **Keiding S**. Hepatic ethanol elimination kinetics in patients with cirrhosis. *Scand J Gastroent* 2009; 44: 867–871.

Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A, Ravn J, Clementsen P, Høgholm A, Larsen K, Rasmussen T, **Keiding S**, Gerke O, Skov B, Steffensen I, Hansen H, Vilmann P, Jacobsen G, Backer V, Maltbaek N, Pedersen J, Madsen H, Nielsen H, Højgaard L. Pre-operative staging of lung cancer with combined PET-CT. *N Engl J Med* 2009; 361: 32–39.

Memon AA, Jakobsen A, Dagnaes-Hansen F, Sorensen BS, **Keiding S**, Nexø E. PET imaging with [<sup>11</sup>C] labeled erlotinib. A micro-PET study on mice with lung tumor xenografts. *Cancer Research* 2009; 69: 873–878.

Bass L, **Keiding S**, Munk OL. Benefits and risks of transforming data from dynamic positron emission tomography, with an application to hepatic encephalopathy. *J Theor Biol* 2009; 256: 632–636.

Bak L, Iversen P, Sørensen M, **Keiding S**, Vilstrup H, Ott P, Gjedde A, Waagepetersen HS, Schousboe A. Metabolic fate of isoleucine in a rat model of hepatic encephalopathy and in cultured neural cells exposed to ammonia. *Metab Brain Dis* 2009; 24: 135–145.

Sørensen M, Munk OL, **Keiding S**. Backflux of ammonia from brain to blood in human subjects with and without hepatic encephalopathy. *Metab Brain Dis* 2009; 24: 237–242.

Iversen P, Sørensen M, Bak LK, Waagepetersen HS, Vafaei MS, Borghammer P, Mouridsen K, Jensen SB, Vilstrup H, Schousboe A, Ott P, Gjedde A, **Keiding S**. Low cerebral oxygen consumption and blood flow in patients with cirrhosis and an acute episode of hepatic encephalopathy. *Gastroenterology* 2009;136:863–871.

Munk OL, **Keiding S**, Bass L. A method to estimate catheter dispersion and to calculate dispersion-free blood time-activity curves. *Medical Physics* 2008; 35: 3471–3481.

Sørensen M, Munk OL, Mortensen FV, Olsen AaK, Bender D, Bass L, **Keiding S**. Hepatic uptake and metabolism of galactose can be quantified in vivo by 2-[<sup>18</sup>F]Fluoro-2-deoxy-galactose positron emission tomography. *Am J Physiol Gastrointest Liver Physiol* 2008; 295:G27–G36.

Busk M, Horsman MR, Jakobsen S, **Keiding S**, van der Kogel AJ, Bussink J, Overgaard J. Imaging hypoxia in xenografted and murine tumors With (18)F-Fluoroazomycin arabinoside: A comparative study involving microPET, autoradiography, pO<sub>2</sub>-polarography, and fluorescence microscopy. *Int J Radiat Oncol Biol Phys* 2008; 70:1202-1212.

Johansen J, Buus S, Loft A, **Keiding S**, Overgaard M, Hansen HS, Grau C, Bundgaard T, Kirkegaard J, Overgaard J. Prospective study of <sup>18</sup>FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study. *Head Neck* 2008; 30: 471–478.

Gjedsted J, Gormsen L, Nielsen S, Schmitz O, Djurhuus, CB, **Keiding S**, Ørskov H, Tønnesen E, Møller, N. Effects of a 3 Day Fast on Regional Lipid and Glucose Metabolism in Human Skeletal Muscle and Adipose Tissue *Acta Physiol* 2007; 191: 205–216.

Sørensen M, Mortensen FV, Høyer M, Vilstrup H, **Keiding** and The Liver Tumor Board at Aarhus University Hospital. FDG-PET improves management

of patients with colorectal liver metastases allocated for local treatment: a consecutive prospective study. *Scand J Surgery* 2007; 96: 209–213.

Johansen ML, Bak LK, Schousboe A, Iversen P, Sørensen M, **Keiding S**, Vilstrup H, Gjedde A, Ott P, Waagepetersen JS. The metabolic role of isoleucine in detoxification of ammonia in cultured mouse neurons and astrocytes. *Neurochem Int* 2007; 50: 1042–1051.

Sørensen M, **Keiding S**. New findings on cerebral ammonia uptake in HE using functional <sup>13</sup>N-ammonia PET. *Metab Brain Dis* 2007; 22: 277–284.

Prytz H, **Keiding S**, Björnsson E, Broomé U, Almer S, Castedal M, Munk OL and The Swedish Internal Medicine Liver Club (SILK). Dynamic FDG PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. *Hepatology* 2006; 44: 1572–1580.

Olsen AaK, Munk OL, **Keiding S**. Effect of hypercapnia on cerebral blood flow and blood volume in pigs studied by PET. *Comparative Medicine* 2006; 56: 416–420.

Iversen P, Hansen DAa, Bender D, Rodell A, Munk OL, Cumming P, **Keiding S**. Peripheral Benzodiazepine receptors in the brain of patients with cirrhosis and manifest hepatic encephalopathy. *Eur J Nucl Med Mol Imaging* 2006; 33: 810–816.

Buus S, Grau C, Munk OL, Rodell A, Jensen K, Mouridsen K, **Keiding S**. Individual radiation response of parotid glands investigated by dynamic <sup>11</sup>C-methionine PET. *Radiother Oncol* 2006; 78: 262–269.

Cumming P, Pedersen MD, Minuzzi L, Mezzomo K, Danielsen EH, Iversen P, Hansen DAa, **Keiding S**, Munk OL, Finsen B. Distribution of PK11195 binding sites in porcine brain studied by autoradiography in vitro and by positron emission tomography. *Synapse* 2006; 59: 418–426.

Hutchings M, Loft A, Hansen M, Pedersen LM, Berthelsen AK, **Keiding S**, D'Amore F, Boesen AM, Roemer L, Specht L. Positron emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. *Haematologica* 2006; 9: 482–489.

**Keiding S**, Sørensen M, Bender D, Munk OL, Ott P, Vilstrup H. Brain metabolism of <sup>13</sup>N-ammonia during acute hepatic encephalopathy in cirrhosis measured by PET. *Hepatology* 2006; 43: 42–50. Correction in *Hepatology* 2006; 44: 1056.

Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, **Keiding S**, D'Amore F, Boesen AM, Specht L. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin Lymphoma. *Blood* 2006; 1: 52–59.

Sørensen M, Horsman MR, Cumming P, Munk OL, **Keiding S**. Effect of intratumoral heterogeneity in oxygenation status on FMISO PET,

autoradiography, and electrode pO<sub>2</sub> measurements in murine tumors. *Int J Radiat Oncol Biol Phys* 2005; 62: 854–861.

**Keiding S**, Munk OL, Vilstrup H, Nielsen DT, Roelsgaard K, Bass L. Hepatic microcirculation assessed by PET of first-pass ammonia metabolism in porcine liver. *Liver Int* 2005; 25: 171–176.

Buus S, Grau C, Munk OL, Bender D, Jensen K, **Keiding S**. <sup>11</sup>C-methionine PET, a novel method for measuring regional salivary gland function after radiotherapy of head and neck cancer. *Radiother Oncol* 2004; 73: 289–296.

Holland-Fischer P, Grønbæk H, Astrup L, **Keiding S**, Nielsen DT, Vilstrup H. Budd-Chiari and inferior caval vein syndromes due to membranous obstruction of the liver veins: successful treatment with angioplasty and transcaval transjugular intrahepatic porto-systemic shunt. *Scand J Gastroenterol* 2004; 39: 1025–1028.

**Keiding S**, Solvig J, Grønbæk H, Vilstrup H. Combined liver vein and spleen pulp pressure measurements in patients with portal or splenic vein thrombosis. *Scand J Gastroenterol* 2004; 39: 594–599.

Grönroos T, Bentzen L, Marjamäki P, Murata R, Horsman MR, **Keiding S**, Eskola O, Haaparanta M, Minn H, Solin O. Comparison of the biodistribution of two hypoxia markers [<sup>18</sup>F]FETNIM and [<sup>18</sup>F]FMISO in an experimental mammary carcinoma. *Eur J Nucl Med Mol Imaging* 2004; 31: 513–520.

Munk OL, Bass L, Feng H, **Keiding S**. Determination of regional flow using intravascular PET tracers: microvascular theory and experimental validation for pig livers. *J Nucl Med* 2003; 44: 1862–1870.

Munk OL, **Keiding S**, Bass L. Capillaries within compartments: microvascular interpretation of dynamic positron emission tomography data. *J Theor Biol* 2003; 225: 127–141.

Munk OL, **Keiding S**, Bass L. Impulse-response function of splanchnic circulation with model-independent constraints: theory and experimental validation. *Am J Physiol Gastrointest Liver Physiol* 2003; 285: G671–G680.

Bentzen L, **Keiding S**, Nordmark M, Falborg L, Hansen SB, Keller J, Nielsen OS, Overgaard J. Tumour oxygenation assessed by <sup>18</sup>F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. *Radiotherapy and Oncology* 2003; 67: 339–344.

Weiss M, Roelsgaard K, Bender D, **Keiding S**. Determinants of [<sup>13</sup>N]ammonia kinetics in hepatic PET experiments: a minimal recirculatory model. *Eur J Nucl Med* 2002; 29: 1648–1656.

Bentzen L, **Keiding S**, Horsman M, Falborg L, Hansen SB, Overgaard J. Assessment of hypoxia in experimental tumors by [<sup>18</sup>F]Fluoromisonidazole PET examination and pO<sub>2</sub> electrode measurements. Influence of tumour volume and carbogen breathing. *Acta Oncologica* 2002; 41: 304–312.

**Keiding S**, Vilstrup H. Intrahepatic heterogeneity of hepatic venous pressure gradient in human cirrhosis. *Scand J Gastroenterol* 2002; 37: 960–964.

Kaarstad K, Bender D, Bentzen L, Munk OL, **Keiding S**. Metabolic Fate of  $^{18}\text{F}$ -FDG in mice bearing either SCCVII squamous cell carcinoma or C3H mammary carcinoma. *J Nucl Med* 2002; 43: 940–947.

**Keiding S**, Munk OL, Roelsgaard K, Bender D, Bass L. Positron emission tomography of hepatic first-pass metabolism of ammonia in pig. *Eur J Nucl Med* 2001; 28: 1770–1775.

Bender D, Munk OL, Feng H, **Keiding S**. Metabolites of  $^{18}\text{F}$ -FDG and 3-O- $^{11}\text{C}$ -methylglucose in pig liver. *J Nucl Med* 2001; 42:1673–1678.

Munk OL, Bass L, Roelsgaard K, Bender D, Hansen SB, **Keiding S**. Liver kinetics of glucose analogs measured in pigs by PET: Importance of dual-input blood sampling. *J Nucl Med* 2001; 42: 795–801.

Bjørø K, Hockerstedt K, Ericzon BG, Friman S, Hjortrup A, **Keiding S**, Schruppf E, Duraj F, Olausson M, Makisalo H, Bergan A, Kirkegaard P. Liver transplantation in patients over 60 years of age. *Transpl Int* 2000; 13 (Suppl 1): 165–170.

Bentzen L, **Keiding S**, Horsman MR, Falborg L, Hansen SB, Overgaard J. Feasibility of detecting hypoxia in experimental mouse tumours with  $^{18}\text{F}$  fluorinated tracers and positron emission tomography. A study evaluating [ $^{18}\text{F}$ ]Fluoromisonidazole and [ $^{18}\text{F}$ ] Fluoro-2-deoxy-D-glucose. *Acta Oncologica* 2000; 39: 629–637.

**Keiding S**, Munk OL, Schjøtt KM, Hansen SB. Dynamic 2- [ $^{18}\text{F}$ ]fluoro-2-deoxy-D-glucose positron emission tomography of liver tumors without blood sampling. *Eur J Nucl Med* 2000; 27: 407–412.

Ott P, Clemmesen O, **Keiding S**. Interpretation of simultaneous measurements of hepatic extraction fractions of indocyanine green and sorbitol. Evidence of hepatic shunts and capillarization. *Dig Dis Sci* 2000; 45: 359–365.

Bjørø K, Friman S, Höckerstedt K, Kirkegaard P, **Keiding S**, Schruppf E, Olausson M, Oksanen A, Isoniemi H, Hjortrup A, Bergan A, Ericzon BG. Liver Transplantations in the Nordic Countries, 1982-1998: Changes of indications and improving results. *Scand J Gastroenterol* 1999; 34: 714–722.

**Keiding S**, Hansen SB, Rasmussen HH, Gee A, Kruse A, Roelsgaard K, Tage-Jensen U, Dahlerup JF. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. *Hepatology* 1998; 28: 700–706.

**Keiding S**, Engsted E, Ott P. Sorbitol as a test substance for measurement of liver plasma flow in humans. *Hepatology* 1998; 28: 50–56.

Ott P, Bass L, **Keiding S**. Hepatic ICG removal in the pig depends on plasma protein and hematocrit: Evidence of sinusoidal binding disequilibrium and unstirred water layer effects. *Hepatology* 1997; 26: 679–690.

**Keiding S**, Höckerstedt K, Bjøro K, Bondesen S, Hjortrup A, Isoniemi H, Erichsen C, Söderdahl G, Ericzon B-J. The nordic multicentre double-blind randomized controlled trial of prophylactic ursodeoxycholic acid in liver transplant patients. *Transplantation* 1997; 63: 1591–1594.

Roelsgaard K, Bøtker HE, Stødkilde-Jørgensen H, Andreasen F, Jensen SL, **Keiding S**. Effects of brain death and glucose infusion on hepatic glycogen and blood hormones in the pig. *Hepatology* 1996; 24: 871–875.

Roelsgaard K, Bøtker HE, Jensen SL, **Keiding S**. Adenine nucleotide breakdown in UW-preserved cold ischemic pig livers: Effects of adenosine  $\alpha$ - and  $\beta$ -methylene-diphosphate. *Res Surgery* 1996; 8: 20–24.

Ott P, Bass L, **Keiding S**. The kinetics of continuously infused indocyanine green in the pig. *J Pharmacokinetics Biopharm* 1996; 24: 19–44.

Kjær M, **Keiding S**, Engfred K, Rasmussen K, Sonne B, Kirkegaard P, Galbo H. Glucose homeostasis during exercise in humans with a liver or kidney transplant. *Am J Phys* 1995; 268: E636–644.

**Keiding S**, Badsberg JH, Becker U, Bentsen KD, Bonnevie O, Caballeria J, Eriksen J, Hardt F, Keiding N, Morgan M, Poulsen H, Ranek L, Rodes J, Schou G, Walker R, Tygstrup N. The prognosis of patients with alcoholic liver disease. An international randomized, placebo-controlled trial on the effect of malotilate on survival. *J Hepatol* 1994; 20: 454–460.

Ott P, **Keiding S**, Johnsen AH, Bass L. Hepatic removal of two fractions of indocyanine after bolus injection in anesthetized pigs. *Am J Physiol* 1994; 266: G1108–1122.

**Keiding S**, Vilstrup H, Lindkær Jensen S. Befolkningens holdning til organdonation og transplantation. *Ugeskr Læger* 1994; 156: 2869–2872.

Hasselbach E, Timm S, Nordentoft M, Roesen A, **Keiding S**, Hemmingsen R. Delirium tremens and physical alcohol withdrawal: A double-blind comparison of phenobarbital and barbital treatment. *Nord J Psychiatry* 1994; 48: 121–130.

Kjær M, Jurlander J, **Keiding S**, Galbo H, Kirkegaard P, Hage E. No reinnervation of sympathetic nerves after liver transplantation in human subjects. *J Hepatol* 1994; 20: 97–100.

Ott P, **Keiding S**, Bass L. Plasma elimination of indocyanine green in the intact pig after bolus injection and during constant infusion: Comparison of

spectrophotometry and HPLC for concentration analysis. *Hepatology* 1993; 18: 1504–1515.

**Keiding S**, Ott P, Bass L. Enhancement of unbound clearance of ICG by plasma protein, demonstrated in human subjects and interpreted without assumption of facilitating structures. *J Hepatol* 1993; 19: 327–344.

Taaning E, Dickmeiss E, **Keiding S**, Kirkegaard P, Thorsgaard N. Liver transplantation after post-transfusion purpura. *Clinical Transplantation* 1993; 7: 253–257.

Kirkegaard P, Hjortrup A, **Keiding S**, Skovby F, Hage E, Secher NH, Heslet L. Levertransplantationer i Danmark. Det første års erfaringer. *Ugeskr Læger* 1993; 155: 684–687.

Ott P, **Keiding S**, Bass L. Intrinsic hepatic clearance of indocyanine green in the pig: Dependence on plasmaprotein concentration. *Eur J Clin Invest* 1992; 22: 347–357.

Dalhoff K, Almdal TP, Bjerrum K, **Keiding S**, Mengel H, Lund J. Pharmacokinetics of paroxetine in patients with cirrhosis. *Eur J Clin Pharmacol* 1991; 41: 351–354.

Fischer-Nielsen A, Poulsen HE, Hansen BA, Hage E, **Keiding S**. CCl<sub>4</sub> cirrhosis in rats; irreversible histological changes and differentiated functional impairment. *J Hepatol* 1990; 12: 110–117.

**Keiding S**, Johansen S, Tygstrup N. Galactose removal kinetics during hypoxia in perfused pig liver: Reduction of V<sub>max</sub>, but not of intrinsic clearance V<sub>max</sub>/K<sub>m</sub>. *Eur J Clin Invest* 1990; 20: 305–309.

**Keiding S**, Ericzon BJ, Eriksson S, Flatmark A, Höckerstedt K, Isoniemi H, Karlberg I, Keiding N, Olsson R, Samela K, Schrupf E, Söderman C. Survival after liver transplantation of patients with PBC in the Nordic countries: Comparison to direct adjusted survival from another series of transplantations and from an international trial of medical treatment. *Scand J Gastroenterol* 1990; 25: 11–18.

Fischer Nielsen A, **Keiding S**, Poulsen HE, Hansen B. Age dependence of rat liver function measurements. *J Hepatol* 1989; 9: 190–197.

**Keiding S**, Henriksen O, Sejrsen P. Muscle capillary permeability for (14 C)inulin and (51 Cr)EDTA in human forearm. *Acta Physiol Scand* 1988; 133: 335–342.

**Keiding S**, Skak C. Methodological limitations of the use of intrinsic hepatic clearance of ICG as a measure of liver cell function. *Eur J Clin Invest* 1988; 18: 507–511.

Bass L, **Keiding S**. Physiologically based models and strategic experiments in hepatic pharmacology. *Biochem Pharmacol* 1988; 8: 1425–1431.

**Keiding S.** Galactose clearance and liver blood flow. *Gastroenterol* 1988; 94: 477–481.

Skak C, **Keiding S.** Methodological problems in the use of indocyanine green to estimate hepatic blood flow and ICG clearance in man. *Liver* 1987; 7: 155–162.

Winkler K, **Keiding S,** Tønnesen K, Tygstrup N. Effect of short lasting hypoxia on the metabolic function of the perfused pig liver. Comparison of ischaemic and hypoxaemic hypoxia. *Eur J Clin Invest* 1986; 16: 106–112.

Winkler K, **Keiding S,** Tønnesen K, Tygstrup N. The effect of physiological temperature changes on the galactose elimination capacity of the isolated perfused pig liver. *Clin Physiol* 1986; 6: 381–387.

**Keiding S.** Species differences of galactose metabolism in erythrocytes. *Scand J Clin Lab Invest* 1985; 45: 697–700.

Hansen BA, Mengel H, **Keiding S,** Lund J. Femoxetine clearance in patients with liver cirrhosis. *Acta Pharmacol et Toxicol* 1984; 55: 386–390.

**Keiding S,** Priisholm K. Current models of hepatic pharmacokinetics: flow effect on kinetic constants of ethanol elimination in perfused rat livers. *Biochem Pharm* 1984; 33: 3209–3212.

**Keiding S,** Steiness E. Flow dependence of propranolol elimination in perfused rat liver. *J Pharmacol Exp Ther* 1984; 230: 474–477.

Poulsen HE, Vilstrup H, **Keiding S.** Galactose elimination kinetics in the perfused rat liver after two thirds hepatectomy. *Scand J Clin Lab Invest* 1984; 44: 155–158.

Geisler C, **Keiding S.** Kolestatisk hepatitis under behandling med meksiletin/lidokain. Kasuistik. *Ugeskr Læger* 1984; 146: 1212–1213.

**Keiding S,** Døssing M, Hardt F. A nurse with liver injury associated with occupational exposure to halothane in a recovery unit. Case report. *Danish Med Bull* 1984; 31: 255–256.

**Keiding S,** Christensen N J, Damgaard S E, Dejgård A, Iversen H L, Jacobsen A, Johansen S, Lundquist F, Rubinstein E, Winkler K. Ethanol metabolism in heavy drinkers after massive and moderate alcohol intake. *Biochem Pharm* 1983; 32: 3097–3102.

**Keiding S,** Mengel H, Lund J. Hepatic elimination of femoxetine in pig during intravenous infusion. *Acta Pharmacol et Toxicol* 1983; 52: 234–237.

Vilstrup H, **Keiding S,** Vendsborg P B. Kinetics of galactose uptake by perfused rat livers: Applicability of a family of models. *J Theor Biol* 1983; 101: 335–344.

Bechgaard E, **Keiding S**, Lund J, Christiansen L A. Hepatic elimination of femoxetine in pig. *Acta Pharm et Toxicol* 1983; 52: 1–7.

Christiansen LA, **Keiding S**, Winkler K. Hepatic elimination of endogenous gastrin in pigs. *Scand J Gastroenterol* 1982; 17: 113–120.

**Keiding S**, Johansen S, Winkler K. Hepatic galactose elimination kinetics in the intact pig liver. *Scand J Clin Lab Invest* 1982; 42: 253–259.

Johansen S, **Keiding S**. A family of models for hepatic elimination kinetics. *J Theor Biol* 1981; 89: 549–556.

Gaub J, Faurholdt L, **Keiding S**, Kondrup J, Petersen P, Wantzin LL. Cytophotometry of liver cells from ethanol fed rats: Ethanol causes increased polyploidization and protein accumulation. *Eur J Clin Invest* 1981; 11: 235–237.

**Keiding S**, Vilstrup H, Hansen L. Importance of flow and hematocrit for metabolic function in perfused rat liver. *Scand J Clin Lab Invest* 1980; 40: 355–359.

**Keiding S**, Johansen S, Midtbøll I, Rabøl A, Christiansen L. Ethanol elimination kinetics in pig liver and human liver. *Am J Physiol* 1979; 237: E316–324.

Hansen TM, **Keiding S**, Lauritzen SL, Manthorpe R, Sørensen SF, Wiik A. Clinical assessment of disease activity in rheumatoid arthritis. *Scand J Rheumatol* 1979; 8: 101–105.

Winkler K, Bass L, **Keiding S**, Tygstrup N. Physiologic basis of clearance measurements in hepatology. *Scand J Gastroenterol* 1979; 14: 439–448.

**Keiding S**, Chiarantini E. Effect of sinusoidal perfusion on galactose elimination kinetics in perfused rat liver. *J Pharm Exp Ther* 1978; 205: 465–470.

Andreasen PB, Rabøl A, Tønnesen K, **Keiding S**. Michaelis Menten kinetics of phenazone elimination by perfused pig liver. *Acta Pharm et Toxicol* 1977; 40: 1–13.

**Keiding S**, Johansen S, Tønnesen K. Kinetics of ethanol inhibition of galactose elimination in perfused pig liver. *Scand J Clin Lab Invest* 1977; 37: 487–494.

**Keiding S**, Johansen S, Winkler K, Tønnesen K, Tygstrup N. Michaelis Menten kinetics of galactose elimination by the isolated perfused pig liver. *Am J Physiol* 1976; 320: 1302–1313.

Bass L, **Keiding S**, Winkler K, Tygstrup N. Enzymatic elimination of substrates flowing through the intact liver. *J Theor Biol* 1976; 61: 393–409.

Vilstrup H, **Keiding S**. Effect of dietary protein depletion on the galactose elimination capacity in intact rats. *J Nutrion* 1976; 106: 1492–1496.

**Keiding S**, Vinterby Aa. Orotate decreases the inhibitory effect of ethanol on galactose elimination in the perfused rat liver. *Biochem J* 1976; 160: 715–720.

Winkler K, Bass L, **Keiding S**, Tygstrup N. La clairance commemeasure du debit hepatic. *Ann Gastroent et d'Hepato* 1975; 11: 427–433.

Tygstrup N, Bass L, **Keiding S**, Winkler K. L'Emploi de la clairance en hepatologie. *Ann Gastroenterol et d'Hepato* 1975; 11: 421–425.

**Keiding S**. The effect of ethanol and fructose on galactose elimination in rat. *Scand J Clin Lab Invest* 1974; 34: 91–96.

**Keiding S**, Keiding N, Tygstrup N. The effect of galactose-ethanol feeding on the nutrition of the rat. *J Nutrion* 1974; 104: 294-299.

Ranek L, Bremmelgaard A, Dupont B, Jørgensen M, **Keiding S**, Thomsen P, Tyrsted G. The effects of azathioprine on CCl<sub>4</sub> induced cirrhosis in rats. *Beiträge zur Pathologie* 1974; 152: 66–73.

**Keiding S**, Andreasen PB, Fauerholdt L. Effect of pheno-barbital induction on galactose elimination in the rat. *Biochem Pharm* 1973; 22: 2293–2297.

**Keiding S**. The galactose elimination capacity in the rat. *Scand J Clin Lab Invest* 1973; 31: 319–325.

**Keiding S**, Mellemgard L. Dose dependence of galactose cataract in the rat. *Acta Ophthalmologica Scand* 1972; 50: 174–182.

Tygstrup N, Funding J, Juul Nielsen J, **Keiding S**, Koudahl G, Ramsøe K, Winkler K. The function of the isolated perfused and in vivo pig liver. *Scand J Gastroenterol* 1971; suppl 9: 131–138.

Tygstrup N, **Keiding S**. Lethal effect of feeding rats on galactose ethanol. *Nature* 1969; 222: 181.

## Book chapters, reviews and editorials

Berding G, Banati RB, Buchert R, Chierichetti F, Grover VP, Kato A, **Keiding S**, Taylor-Robinson SD; International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN). Radiotracer imaging studies in hepatic encephalopathy: ISHEN practice guidelines. *Liver Int* 2009; 21:621–628.

Sørensen M, Mortensen FV, Høyer M, Vilstrup H, **Keiding S**. Positronemissionstomografi har klinisk betydning ved planlægning af behandling af kolorektale levermetastaser – sekundærpublikation. *Ugeskr Læger* 2008; 170: 1364–1366.

Sørensen M, Vilstrup H, **Keiding S**, Ott P. Hepatisk encefalopati. *Ugeskr Læger* 2007, 1106.

Sørensen M, **Keiding S**. Positron emission tomography of the liver. In: Rodés J, Benhamou JP, Blei A, Reichen J, Rizzetto M (eds.) *Textbook of Hepatology: From Basic Science to Clinical Practice*, 3. edition, Blackwell Publishing 2007, pp. 561–566.

**Keiding S**, Sørensen M. Hepatic removal kinetics: Importance for quantitative measurements of liver function. In: Rodés J, Benhamou JP, Blei A, Reichen J, Rizzetto M (eds.) *Textbook of Hepatology: From Basic Science to Clinical Practice*, 3. edition, Blackwell Publishing 2007, pp. 468–478.

Sørensen M, **Keiding S**. Ammonia metabolism in cirrhosis. In: Häussinger D, Kircheis G, Schliess F (eds.) *Hepatic Encephalopathy and Nitrogen Metabolism*, Springer 2006: pp. 406–419.

Grønbæk H og Levertumorgruppen Århus Sygehus. Hepatocellulært carcinom og andre levertumorer. *Ugeskr Læger* 2006; 168: 1219.

**Keiding S**, Becker U, Jacobsen BA, Hamberg O, Larsen FS, Rasmussen TN, Møller S (Bestyrelsen for Dansk Selskab for Hepatologi, DASL). Funktionel billeddannelse af leveren med positronemissionstomografi. *Ugeskr Læger* 2005; 167: 1390.

Bestyrelsen for Dansk Selskab for Hepatologi (DASL): Christensen E, Bucharth F, Henriksen JH, Jacobsen BA, **Keiding S**, Møller S, Ott P. Sengstakensonde. *Ugeskr Læger* 2004; 166: 470–472.

**Keiding S**. New perspectives in the use of PET in hepatology. In: *International conference: New Trends and Perspectives in Hepatology*. University of Padova, Italy. November 24-25, 2003.

Munk, OL, **Keiding S**, Hansen SB. Bayesian estimation of kinetic rate constants using PET and compartmental models. *Brain Imaging Using PET*. Academic Press, Elsevier Science, USA, 2002, pp 93-99.

**Keiding S**, Hansen SB, Rasmussen HH, Gee A, Kruse A, Roelsgaard K, Tage-Jensen U, Dahlerup JF. Detektion af kolangiocarcinom ved primær

scleroserende cholangitis ved hjælp af positron emission tomography (PET). *Ugeskr Læger* 2000; 162: 782–785.

Gee A, **Keiding S**. A simple and rapid method for the determination of [<sup>13</sup>N]ammonia and metabolites in blood. *J Labelled Cpd Radiopharm* 1999; 42 (suppl.1): pp. 222–224.

Eigtved A, **Keiding S**, Kanstrup IL, Daugaard G, Højgaard L. PET-scanning til cancerdiagnostik. *Ugeskr Læger* 1999; 161: 6166–6168.

**Keiding S**, Schiøtt KM, Vilstrup H, Gjedde A. Positronemissionstomografi af levertumorer. *Ugeskr Læger* 1999; 161: 6163–6165.

**Keiding S**, Lauterburg BH. Hepatic removal of circulating substances: importance for quantitative measurements of liver function. In: McIntyre N, Benhamou J-P, Bircher J, Rizzetto M, Rodés J (eds) *Oxford Textbook of Clinical Hepatology*. 2. edition. Oxford University Press 1998, pp. 523–532.

Kjær M, Fernandes A, Secher NH, **Keiding S**, Kirkegaard P, Beyer N, Galbo H. Sympathetic liver innervation and regulation of hepatic glucose production during exercise - human experiments with pharmacological blockade and liver denervation. In: Shimazu T (ed.) *Liver Innervation*. John Libbey and Co. Ltd 1996; pp. 465–469.

**Keiding S**. Drug administration to liver patients: Aspects of liver pathophysiology. *Seminars in Liver Disease* 1995; 15: 268–282.

Berglin E, Nilsson F, Bergh CH, Martensson G, Ahlmen J, Gabel H, Karlberg I, **Keiding S**. Prioritering vid organtransplantationer. *Nordisk Med* 1994; 109: 338-340.

**Keiding S**. Dynamic aspects of hepatic removal of circulating substances. In: McIntyre N, Benhamou J P, Bircher J, Rizzetto M, Rodes J (eds) *Oxford Textbook of Clinical Hepatology*. Oxford University Press 1991, pp. 78–87.

**Keiding S**. Can intrahepatic shunting be measured? Editorial. *Dig Dis Sci* 1991; 36: 1185–1188.

Lægeforeningen (Gjerris F, **Keiding S**, Mortensen S Aa, Rasmussen K, Hjelmars B, Albinus S). Hjernedøds-kriterium og organtransplantation. En vejledende redegørelse til landets læger. *Ugeskr Læger* 1990; 152: 2663–2678.

Höckerstedt K, Ericzon B-G, Eriksson S, Flatmark A, Isonieni H, Karlberg I, Keiding N, **Keiding S**, Olsson R, Salmela K, Schrupf E, Söderman C. Survival after liver transplantation for primary biliary cirrhosis: Use of prognostic indices for comparison with medical treatment. *Transpl Proc* 1990; 22: 1499–1500.

Lamm L A, **Keiding S**, Mortensen S Aa. Organtransplantation. *Månedskrift for praktisk lægegerning* 1990: 65–76.

**Keiding S.** Mathematical modelling of liver function. In: Molino G, Avagnino P (eds.) *Systematic and Quantitative Hepatology, Pathophysiological and Methodological Aspects*. Masson, Milano 1989 pp. 227–233.

**Keiding S,** Rasmussen K, Mortensen S Aa. Hvorfor skal vi organtransplantere? *Ugeskr Læger* 1989; 151: 2609–2611.

**Keiding S.** Report from the 2nd workshop on quantitative evaluation of metabolism in the intact liver. *Eur J Clin Invest* 1989; 19: 503–515.

**Keiding S,** Freund L, Hobolth N, Holsteen V, MacIntyre B H, Kirkegaard P, Muff Nielsen M, Rokkjær M, Schaffalitzky de Muckadell O B, Skovby F, Sørensen T I A, et al. Levertransplantation af danskere i udlandet. *Ugeskr Læger* 1989; 151: 360–362.

**Keiding S,** Boesby S, Jensen SL, Kirkegaard P. European Society for Organ Transplantation: Levertransplantation. Gøteborg juni 87. *Ugeskr Læger* 1987; 149: 2268.

**Keiding S.** Hepatic clearance and liver blood flow. Editorial. *J Hepatol* 1987; 4: 393–398.

**Keiding S,** Boesby S, Degn H, Jensen SL, Kirkegaard P. Levertransplantation. *Ugeskr Læger* 1986; 148: 941–944.

Tygstrup N, Ranek L, Juhl E, **Keiding S,** Christensen E, Williams R, Neuberger J, Rodes J. Ciclosporin (CyA) in primary biliary cirrhosis (PBC): A multicentre, double blind, placebo controlled long term therapeutic study. The study design. In: Schinkler R (ed.) *Ciclosporin in autoimmune diseases*. Springer Verlag 1985, pp. 182–184.

Lund J, Mengel H, Østergaard O, Balling H, Skausig OB, **Keiding S,** Hansen B A. Kinetics of femoxetine in elderly volunteers and in patients with renal and hepatic dysfunction. In: Borrows and Norman (eds.) *Biological Psychiatry - New Prospects, Clinical and Pharmacological Studies in Psychiatric Disorders*. John Libbey 1985, pp. 347–352.

Gammeltoft S, **Keiding S,** Tygstrup N. Carbohydrate metabolism in relation to liver physiology and disease. In: Arias IM, Frenkel M, Wilson JHP (eds.) *Liver Annual 4*. Amsterdam: Elsevier 1984, pp. 1–37.

**Keiding S.** Ethanol metabolism in the human liver. In: *Metabolic Effects of Alcohol*. Current review. North Holland, Elsevier: Biomedical Press 1979, pp. 293–302.

**Keiding S,** Andreasen P B. Hepatic clearance measurements and pharmacokinetics. *Pharmacology* 1979; 19: 105–110.

Winkler K, Bass L, **Keiding S,** Tygstrup N. The regimes of hepatic clearance: Definitions and clinical significance. In: Preisig R, Paumgartner G (eds.) *The*

*Liver, Quantitative Aspects of Structure and Function (II)*. Basel; Karger 1976, pp. 128–129.

**Keiding S**, Bass L, Winkler K, Tygstrup N. Enzymatic elimination of substrates flowing through the intact liver. In: Preisig R, Bircher J, Paumgartner G (eds.) *The Liver, Quantitative Aspects of Structure and Function (II)*: Basel; Karger 1976, pp. 126–127.

**Keiding S**. Hepatic elimination kinetics: The influence of hepatic blood flow on clearance determinations. Editorial. *Scand J Clin Lab Invest* 1976; 36: 113–117.

Winkler K, Bass L, **Keiding S**, Tygstrup N. The effect of hepatic perfusion on assessment of kinetic constants. In: Lundquist F, Tygstrup N (eds.) *Regulation of hepatic metabolism* (VI Alfred Benzon Symposium) Copenhagen: Munksgaard 1974, pp. 797–807.

**Keiding S**, Tønnesen K, Hansen FV, Vinterby Aa, Tygstrup N. Modification of galactose elimination kinetics by ethanol in the perfused pig liver. In: Lundquist F, Tygstrup N (eds.) *Regulation of hepatic metabolism* (VI Alfred Benzon Symposium) Copenhagen: Munksgaard 1974, pp. 324–333.

Tygstrup N, Hansen FV, Tønnesen K, **Keiding S**. Kinetics of galactose metabolism in the perfused pig liver. In: Lundquist F, Tygstrup N (eds.) *Regulation of hepatic metabolism* (VI Alfred Benzon Symposium) Copenhagen: Munksgaard 1974, pp. 314–323.

Tygstrup N, Ranek L, Ramsøe K, **Keiding S**. The effect of submaximal elimination of ethanol on hepatic redox levels in man. In: *Alcohol and aldehyde metabolizing systems*. London/New York: Academic Press 1974, pp. 469–481.

Winkler K, **Keiding S**, Tygstrup N. Clearance as a quantitative measure of liver function. In: *The Liver, Quantitative Aspects of Structure and Function (I)*. Basel: Karger 1973, pp. 144–155.

**Keiding S**, Hansen FV, Tønnesen K, Tygstrup N. Experimental studies of galactose elimination capacity as a quantitative measure of hepatocellular function. In: Preisig R, Paumgartner G (eds.) *The Liver, Quantitative Aspects of Structure and Function (I)*. Basel; Karger 1973, pp. 156–163.

## Letters to the Editor

Sørensen M, **Keiding S**. Reply to letter-to-the Editor by Lockwood A, Wack D. The brain permeability-surface product for ammonia. *Hepatology* 2006, 44: 1053–1054.

**Keiding S**, Vilstrup H. Intrahepatic heterogeneity of hepatic venous pressure gradient in human cirrhosis again. *Scand J Gastroenterol* 2002; 37: 1344–1346.

Munk OL, **Keiding S**. Quantification of <sup>18</sup>F-FDG uptake in the liver using dynamic PET. Letter to the Editor. *J Nucl Med* 2002; 43: 439–441.

**Keiding S**, Hansen SB, Dahlerup JF. Detection of cholangiocarcinoma in primary cholangitis by positron emission tomography. *Hepatology* 1999; 29: 611–613.

**Keiding S**. Does prophylactic ursodeoxycholic acid treatment of liver transplant patients prevent acute rejection? *Hepatology* 1998; 27: 1748–1749.

**Keiding S**. Sorbitol clearance: Shift from flow-limitation in controls to enzyme-flow dependence in cirrhosis. *Gastroent* 1989; 96: 1227–1228.

**Keiding S**. Galactose clearance and liver blood flow. Reply to Letter-to-the Editor. *Gastroent* 1988; 95: 1158.

**Keiding S**, Bass L. Galactose clearance as a measure of hepatic blood flow. *Gastroent* 1983; 85: 986–987.